Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E–mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary ana...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tabernero, Josep, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod Kyrre, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Elez, Elena, Gollerkeri, Ashwin, Maharry, Kati, Christy-Bittel, Janna, Kopetz, Scott
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2021
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078423/
https://ncbi.nlm.nih.gov/pubmed/33503393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02088
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados